Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare diseaseMarket Watch • 08/12/24
Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy OpportunitySeeking Alpha • 07/29/24
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024GlobeNewsWire • 06/24/24
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/24
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024GlobeNewsWire • 06/03/24
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024GlobeNewsWire • 05/30/24
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismGlobeNewsWire • 05/14/24
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialGlobeNewsWire • 05/13/24
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024GlobeNewsWire • 05/09/24
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024GlobeNewsWire • 04/25/24
United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismGlobeNewsWire • 04/24/24
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?Market Watch • 04/10/24
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024GlobeNewsWire • 03/04/24
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 02/15/24